Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base

With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.

X-ray lung cancer

As it moves into its next stage of life as an oncology player, Boehringer Ingelheim GMBH is prioritizing lung cancer, with hopes of building a strong franchise upon a base of targeted EGFR drugs – Gilotrif and olmutinib, the third-generation follow-on drug in-licensed from Hanmi Pharmaceutical Co. Ltd.

Approval of Boehringer’s Gilotrif/Giotrif (afatinib) in July 2013 for NSCLC with EGFR mutations marked Boehringer’s entry into the oncology...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category